Investor profile for Visionary Ventures: stage-based planning range, investment stages, sector focus, portfolio companies, sources, and verification status. Part of the Venture Capital Tracker directory.

VC fund profile · evidence-aware directory data

Visionary Ventures stages, portfolio and investment profile

Newport Beach life-sciences venture firm (founded 2016, Octane lineage) investing Series A through commercialization in ophthalmology, medical aesthetics, cardiovascular, and neurovascular companies. Public materials cite ~$30M Fund I, ~$150M Fund II, and a planned $250M Fund III (Jun 2025 OCBJ). Leverages 75+ ophthalmology KOL investor-partners for diligence and deal flow in OC's medtech cluster.

Keep track of Visionary Ventures

Save this profile to your VCT watchlist for a quick return.

View watchlist

Stage-based planning range

$1M–$10M

This is a planning range inferred from stage coverage, not a firm-disclosed check size.

Methodology: Stage bucket inferred from the rounds a fund leads or invests in.

No firm-specific check-size disclosure is recorded.

Source link not recorded Confidence: 25% Verified: Not recorded View methodology

Investment stages

Leads: Series A, Series B

Participates: Seed, Series A, Series B, Growth

Sector focus

healthtech · biotech-life-sciences

Geography

Newport Beach, CA

Founded 2016

Fund size / AUM

~$180M+ across Fund I–II (indicative; Fund III targeting $250M)

A separate fund-size evidence record is not yet available.

Portfolio in our directory

None yet

Linked startup profiles

Latest fund vehicle

Not recorded

Vehicle name, size, and vintage are not yet structured.

Recent tracked investment

Not recorded

No dated round explicitly links this fund.

Rounds they lead

Series A Series B

Rounds they invest

Seed Series A Series B Growth

Last verified: Not recorded. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.

By Venture Capital Tracker

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.